{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:32:20Z","timestamp":1793428340606,"version":"4.5.0"},"reference-count":28,"publisher":"American Association of Avian Pathologists (AAAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Avian Diseases"],"published-print":{"date-parts":[[2023,6,14]]},"abstract":"<jats:p>Eficacia protectora de las vacunas recombinantes HVT-ND-LT y las vacunas con virus vivo atenuado con origen en cultivo de tejidos contra el virus de la laringotraque\u00edtis infecciosa cuando son administradas individualmente o en combinaci\u00f3n. La laringotraque\u00edtis infecciosa (ILT) es una enfermedad respiratoria que causa importantes p\u00e9rdidas econ\u00f3micas a la industria av\u00edcola. El control de la enfermedad se logra mediante la vacunaci\u00f3n y la implementaci\u00f3n de medidas de bioseguridad. El uso de vacunas con el herpesvirus de pavo recombinante (rHVT) bivalentes y trivalentes que expresan genes del virus de la laringotraque\u00edtis infecciosa (ILTV) ha aumentado en todo el mundo. En los Estados Unidos, los programas de vacunaci\u00f3n de aves de larga vida (reproductoras pesadas y aves de postura comerciales) contra la laringotraque\u00edtis incluyen inmunizaciones con vacunas con vector HVT recombinante, ya sea in ovo o al d\u00eda de edad en la planta incubadora, o la aplicaci\u00f3n de vacunas vivas atenuadas administradas a trav\u00e9s del agua de bebida (origen en embri\u00f3n de pollo [CEO]) o por gota ocular (origen en cultivo de tejidos [TCO]). Se ha demostrado que la eficacia de la vacuna rHVT-LT bivalente aplicada al d\u00eda de edad en incubadora, seguida de la inmunizaci\u00f3n con la vacuna CEO en el agua de bebida o por gota ocular, proporciona una protecci\u00f3n m\u00e1s s\u00f3lida que la aplicaci\u00f3n \u00fanicamente de la vacuna rHVT-LT. El objetivo de este estudio fue evaluar la eficacia protectora de una vacuna recombinante rHVT-ND-LT trivalente comercial cuando se administr\u00f3 al d\u00eda de vida seguido de la vacunaci\u00f3n con la vacuna TCO mediante gota ocular a las 10 semanas de edad. Los grupos vacunados \u00fanicamente con la vacuna rHVT-ND-LT, con TCO, la combinaci\u00f3n con rHVT-ND-LT + TCO y un grupo de pollos no vacunados fueron desafiados con una cepa virulenta del virus de la laringotraque\u00edtis a las 15 semanas de edad. Despu\u00e9s del desaf\u00edo, se previno la mortalidad \u00fanicamente en el grupo de pollos vacunados con la combinaci\u00f3n rHVT-ND-LT + TCO. Los signos cl\u00ednicos de la enfermedad y la replicaci\u00f3n del virus de desaf\u00edo en la tr\u00e1quea se redujeron significativamente en los grupos de pollos vacunados con la combinaci\u00f3n rHVT-ND-LT + TCO y con la vacuna TCO. Para evaluar la transmisi\u00f3n del virus de desaf\u00edo, pollos sin contacto previo al virus se introdujeron en todos los grupos vacunados inmediatamente despu\u00e9s del desaf\u00edo. A los 8 d\u00edas posteriores a la introducci\u00f3n, se evidenci\u00f3 la infecci\u00f3n de los pollos sin contacto previo que se introdujeron en los grupos que recibieron \u00fanicamente la vacuna rHVT-ND-LT o la vacuna TCO, pero se previno en el grupo con la combinaci\u00f3n rHVT-ND-LT + TCO. En general, estos resultados indicaron que, en comparaci\u00f3n con las vacunas rHVT-ND-LT o TCO cuando se administran solas, la estrategia de vacunaci\u00f3n rHVT-ND-LT + TCO mejor\u00f3 la protecci\u00f3n contra la enfermedad y redujo la diseminaci\u00f3n del virus de desaf\u00edo.<\/jats:p>","DOI":"10.1637\/aviandiseases-d-23-00010","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T09:20:06Z","timestamp":1686734406000},"page":"145-152","source":"Crossref","is-referenced-by-count":0,"title":["Protection Efficacy of Recombinant HVT-ND-LT and the Live Attenuated Tissue Culture Origin Vaccines Against Infectious Laryngotracheitis Virus When Administered Individually or in Combination"],"prefix":"10.1637","volume":"67","author":[{"given":"Roel","family":"Becerra","sequence":"first","affiliation":[{"name":"Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, University of Georgia, 953 College Station, Athens, GA 30602"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, University of Georgia, 953 College Station, Athens, GA 30602"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricarmen","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, University of Georgia, 953 College Station, Athens, GA 30602"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1212","reference":[{"key":"3","doi-asserted-by":"crossref","unstructured":"JS Guy, HJ Barnes, LM Morgan,  \"Avian Dis.\"  34, \"Virulence of infectious laryngotracheitis viruses: comparison of modified-live vaccine viruses and North Carolina field isolates.\" 106 (1990)","DOI":"10.2307\/1591340"},{"key":"21","doi-asserted-by":"crossref","unstructured":"KJ Livak  and TD Schmittgen  \"Methods.\"  25, \"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.\" 402 (2001)","DOI":"10.1006\/meth.2001.1262"},{"key":"24","doi-asserted-by":"crossref","unstructured":"DI Johnson, A Vagnozzi, F Dorea, et al.  \"Avian Dis.\"  54, \"Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines.\" 1251 (2010)","DOI":"10.1637\/9401-052310-Reg.1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"A Vagnozzi, G Zavala, SM Riblet, et al.  \"Avian Pathol.\"  41, \"Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens.\" 21 (2012)","DOI":"10.1080\/03079457.2011.631983"},{"key":"4","doi-asserted-by":"crossref","unstructured":"JS Guy, HJ Barnes, L Smith,  \"Avian Dis.\"  35, \"Increased virulence of modified-live infectious laryngotracheitis vaccine virus following bird-to-bird passage.\" 348 (1991)","DOI":"10.2307\/1591188"},{"key":"16","doi-asserted-by":"crossref","unstructured":"I Oldoni, A Rodr\u00edguez-Avila, SM Riblet, et al.  \"Avian Pathol.\"  38, \"Pathogenicity and growth characteristics of selected infectious laryngotracheitis virus strains from the United States.\" 47 (2009)","DOI":"10.1080\/03079450802632031"},{"key":"5","doi-asserted-by":"crossref","unstructured":"A Rodr\u00edguez-Avila, I Oldoni, S Riblet, et al.  \"Avian Dis.\"  51, \"Replication and transmission of live attenuated infectious laryngotracheitis virus (ILTV) vaccines.\" 905 (2007)","DOI":"10.1637\/8011-041907-REGR.1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"M Garc\u00eda  and G Zavala  \"Avian Dis.\"  63, \"Commercial vaccines and vaccination strategies against infectious laryngotracheitis: what we have learned and knowledge gaps that remain.\" 325 (2019)","DOI":"10.1637\/11967-090218-Review.1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"VA Palomino-Tapia, G Zavala, S Cheng, et al.  \"Avian Pathol.\"  48, \"Long-term protection against a virulent field isolate of infectious laryngotracheitis virus induced by inactivated, recombinant, and modified live virus vaccines in commercial layers.\" 209 (2019)","DOI":"10.1080\/03079457.2019.1568389"},{"key":"10","doi-asserted-by":"crossref","unstructured":"M Esaki, L Noland, T Eddins, et al.  \"Avian Dis.\"  57, \"Safety and efficacy of a turkey herpesvirus vector laryngotracheitis vaccine for chickens.\" 192 (2013)","DOI":"10.1637\/10383-092412-Reg.1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"D Maekawa, SM Riblet, L Newman, et al.  \"Avian Pathol.\"  48, \"Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination.\" 573 (2019)","DOI":"10.1080\/03079457.2019.1644449"},{"key":"2","doi-asserted-by":"crossref","unstructured":"M Garc\u00eda  and S Spatz  \"Diseases of poultry.\"  \"Infectious laryngotracheitis.\" 189 (2020)","DOI":"10.1002\/9781119371199.ch5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"M Garcia, SJ Spatz, Y Cheng, et al.  \"J Gen Virol.\"  97, \"Attenuation and protection efficacy of ORF C gene-deleted recombinant of infectious laryngotracheitis virus.\" 2352 (2016)","DOI":"10.1099\/jgv.0.000521"},{"key":"17","doi-asserted-by":"crossref","unstructured":"L Reed  and H Muench  \"Am J Trop Med Hyg.\"  27, \"A simple method of estimating fifty percent end-points.\" 493 (1938)","DOI":"10.1093\/oxfordjournals.aje.a118408"},{"key":"28","doi-asserted-by":"crossref","unstructured":"D Maekawa, G Beltr\u00e1n, SM Riblet, et al.  \"Avian Dis.\"  63, \"Protection efficacy of a recombinant herpesvirus of turkey vaccine against infectious laryngotracheitis virus administered in ovo to broilers at three standardized doses.\" 351 (2019)","DOI":"10.1637\/12029-011119-Reg.1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"AF Islam, B Harrison, BF Cheetham, et al.  \"J Virol Methods.\"  119, \"Differential amplification and quantitation of Marek's disease viruses using real-time polymerase chain reaction.\" 103 (2004)","DOI":"10.1016\/S0166-0934(04)00084-9"},{"key":"1","doi-asserted-by":"crossref","unstructured":"AJ Davison, R Eberle, B Ehlers, et al.  \"Arch. Virol.\"  154, \"The order Herpesvirales.\" 171 (2009)","DOI":"10.1007\/s00705-008-0278-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"JL Chac\u00f3n  and AJP Ferreira  \"Vaccine.\"  27, \"Differentiation of field isolates and vaccine strains of infectious laryngotracheitis virus by DNA sequencing.\" 6731 (2009)","DOI":"10.1016\/j.vaccine.2009.08.083"},{"key":"7","doi-asserted-by":"crossref","unstructured":"C Neff, C Sudler, RK Hoop,  \"Avian Dis.\"  52, \"Characterization of western European field isolates and vaccine strains of avian infectious laryngotracheitis virus by restriction fragment length polymorphism and sequence analysis.\" 278 (2008)","DOI":"10.1637\/8168-110107-Reg.1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"I Oldoni, A Rodr\u00edguez-Avila, S Riblet, et al.  \"Avian Dis.\"  52, \"Characterization of infectious laryngotracheitis virus (ILTV) isolates from commercial poultry by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP).\" 59 (2008)","DOI":"10.1637\/8054-070607-Reg"},{"key":"9","doi-asserted-by":"crossref","unstructured":"M Bublot, N Pritchard, DE Swayne, et al.  \"Ann. N. Y. Acad. Sci.\"  1081, \"Development and use of fowlpox vectored vaccines for avian influenza.\" 193 (2006)","DOI":"10.1196\/annals.1373.023"},{"key":"12","doi-asserted-by":"crossref","unstructured":"R Hein, R Koopman, M Garc\u00eda, et al.  \"Avian Dis.\"  65, \"Review of poultry recombinant vector vaccines.\" 438 (2021)","DOI":"10.1637\/0005-2086-65.3.438"},{"key":"13","doi-asserted-by":"crossref","unstructured":"L Gergen, S Cook, B Ledesma, et al.  \"Avian Pathol.\"  48, \"A double recombinant herpes virus of turkeys for the protection of chickens against Newcastle, infectious laryngotracheitis and Marek's diseases.\" 45 (2018)","DOI":"10.1080\/03079457.2018.1546376"},{"key":"15","doi-asserted-by":"crossref","unstructured":"D Maekawa, SM Riblet, P Whang, et al.  \"Avian Dis.\"  65, \"A cell line adapted infectious laryngotracheitis virus strain (B\u0394ORFC) for in ovo and hatchery spray vaccination alone or in combination with a recombinant HVT-LT vaccine.\" 500 (2021)","DOI":"10.1637\/aviandiseases-D-20-00050"},{"key":"18","doi-asserted-by":"crossref","unstructured":"D Maekawa, P Whang, SM Riblet, et al.  \"Avian Pathol.\"  50, \"Assessing the infiltration of immune cells in the upper trachea mucosa after infectious laryngotracheitis virus (ILTV) vaccination and challenge.\" 540 (2021)","DOI":"10.1080\/03079457.2021.1989379"},{"key":"22","unstructured":"\"GraphPad Prism, version 8.\"  (2018)"},{"key":"26","doi-asserted-by":"crossref","unstructured":"C Barboza-Solis, SM Najimudeen, A Perez-Contreras, et al.  \"Vaccines.\"  9, \"Evaluation of recombinant herpesvirus of turkey laryngotracheitis (rHVT-LT) vaccine against genotype VI Canadian wild-type infectious laryngotracheitis virus (ILTV) infection.\" 1425","DOI":"10.3390\/vaccines9121425"},{"key":"27","doi-asserted-by":"crossref","unstructured":"D Maekawa, SM Riblet, P Whang, et al.  \"Vaccines.\"  9, \"Activation of cytotoxic lymphocytes and presence of regulatory t cells in the trachea of non-vaccinated and vaccinated chickens as a recall to an infectious laryngotracheitis virus (ILTV) challenge.\" 865","DOI":"10.3390\/vaccines9080865"}],"container-title":["Avian Diseases"],"original-title":[],"link":[{"URL":"https:\/\/bioone.org\/journals\/avian-diseases\/volume-67\/issue-2\/aviandiseases-D-23-00010\/Protection-Efficacy-of-Recombinant-HVT-ND-LT-and-the-Live\/10.1637\/aviandiseases-D-23-00010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:49:24Z","timestamp":1793425764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/avian-diseases\/volume-67\/issue-2\/aviandiseases-D-23-00010\/Protection-Efficacy-of-Recombinant-HVT-ND-LT-and-the-Live\/10.1637\/aviandiseases-D-23-00010.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8,4]]}},"URL":"https:\/\/doi.org\/10.1637\/aviandiseases-d-23-00010","relation":{},"ISSN":["0005-2086","1938-4351"],"issn-type":[{"value":"0005-2086","type":"print"},{"value":"1938-4351","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}